Decision approving the import and use of the medicinal product Bamlanivimab and Etesevimab for the treatment of COVID-19 The Minister of Health, having regard to the law of 25 March 1964 on the medicinal products, Article 6quater, Paragraph 1, paragraph 5°; having regard to the Royal Decree of 14 December 2006 on medicinal products for human and veterinary use, Article 110, paragraph 3; having regard to the opinion of the Finance inspector given on September 2021; having regard to the laws of the Council of State, coordinated on 12 January 1973, Article 3, § 1; Considering the urgent need; Considering the current pandemic situation of COVID-19, a disease caused by the SARS-CoV-2 virus, in Belgium and the rest of the world; Whereas the disease-infecting and contagious character of the SARS-CoV-2 virus, are different variants circulating in Europe (see: https://www.ecdcdcdc.europa.eu/en/COVID-19/variants-group) and the significant impact on the portability, severity and/ority of theSee https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-limited-antibody-combination-bamlanivimab/etesevimab-COVID19-article-53-procedure-assessment-report_en.pdf; Whereas the Scientific Opinion of 16/03/2021 of the Committee for Medicinal Products for Human Use (CHMP) established at the European Medicines Agency (EMA), which concludes that, on the basis of available preliminary data from the ongoing clinical trial, the recommendations regarding the use, target population and safety monitoring of this veterinary antibody combination may be used as an annex to the same opinion of the CHMP (see https://www.ema.eu/en/documents/referral/eli-lim-comb/e-comment-comment-comment-combination of COVID-19; whereas the recommendations concerning the use, distribution, target population, as well as well as an annex to the same opinion of the CHIMP (see https://www.europa.eu/en/documents/lei-s/lei-comb-s-comb-s-comb-s-comb-s-s-comb-comb-s of COVID-comb-comb-s-s-s-com-s-s-s-comi-s-s-comi-s-comb-comb-s-s-s-s-s-sol-sol-solWhereas, at the end of September 2021, the Belgian State should have a strategic stock of monoclonal antibodies, which should be supplied as soon as possible according to the needs of the hospitals, in order to allow patients suffering from SARS-Cov-2 and developing a serious form of COVID-19 to be treated as soon as possible; hereby decides to allow the import, procurement, delivery and administration of combination of monoclonal antibodies Bamlanivimab and Eteseximab for the treatment of COVID-19 caused by the SARS-Cov-2 virus, UNDER THE FOLLOWING CONDITIONS: 1° the medicinal products combination Bamlanivimab and Eteseximab can only be prescribed by a doctor attached to a hospital, as referred to in Article 2 of the Coordinated Law of 10 July 2008 on hospitals and other care institutions, and after a preliminary opinion, a multidisciplinary expert panel consisting of doctors, as referred to in Article 4 of the Coordinated Law of 10 July 2008 on hospitals and other care institutions.The hospitals shall draw up monthly follow-up reports of the treatments administered to patients treated with the medicinal products Bamlanivimab and Etesevimab. These reports shall contain only anonymised, aggregated data, and shall include at least: the suspected adverse reactions identified, the mortality rates within 29 days of administration and the intake of intensive care within 29 days of administration. These reports shall be transmitted monthly to the FAGG. 6° in the case of a marketing authorisation, as provided for in Article 3 (1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, for the medicinal product in question, shall be issued to Bamlanivimab and Etesevimab, which shall be the packaging of the non-approved medicinal products Bamlanivimab and Etesevimab which are still available in the strategic stock of the Belgian State at the time of granting the said authorisation and used in accordance with the terms of this decision.